Literature DB >> 16052679

Antibody to eosinophil cationic protein suppresses dextran sulfate sodium-induced colitis in rats.

Kazuko Shichijo1, Kazuya Makiyama, Chun-Yang Wen, Mutsumi Matsuu, Toshiyuki Nakayama, Masahiro Nakashima, Makoto Ihara, Ichiro Sekine.   

Abstract

AIM: To produce an antibody against rat eosinophil cationic protein (ECP) and to examine the effects of the antibody in rats with dextran sulfate sodium (DSS)-induced colitis.
METHODS: An antibody was raised against rat ECP. Rats were treated with 3% DSS in drinking water for 7 d and received the antibody or normal serum. The colons were examined histologically and correlated with clinical symptoms. Immunohistochemistry and Western blot analysis were estimated as a grade of inflammation.
RESULTS: The ECP antibody stained the activated eosinophils around the injured crypts in the colonic mucosa. Antibody treatment reduced the severity of colonic ulceration and acute clinical symptoms (diarrhea and/or blood-stained stool). Body weight gain was significantly greater and the colon length was significantly longer in anti-ECP-treated rats than in normal serum-treated rats. Expression of ECP in activated eosinophils was associated with the presence of erosions and inflammation. The number of Ki-67-positive cells in the regenerated surface epithelium increased in anti-ECP-treated rats compared with normal serum-treated rats. Western blot analysis revealed reduced expression of macrophage migration inhibitory factor (MIF) in anti-ECP-treated rats.
CONCLUSION: Our results indicate that treatment with ECP antibody, improved DSS-induced colitis in rats, possibly by increasing the regenerative activity of the colonic epithelium and downregulation of the immune response, and suggest that anti-ECP may promote intestinal wound healing in patients with ulcerative colitis (UC).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16052679      PMCID: PMC4398699          DOI: 10.3748/wjg.v11.i29.4505

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  38 in total

1.  Activated eosinophils in inflammatory bowel disease: do they matter?

Authors:  P Desreumaux; S Nutten; J F Colombel
Journal:  Am J Gastroenterol       Date:  1999-12       Impact factor: 10.864

2.  A pathological function for eotaxin and eosinophils in eosinophilic gastrointestinal inflammation.

Authors:  S P Hogan; A Mishra; E B Brandt; M P Royalty; S M Pope; N Zimmermann; P S Foster; M E Rothenberg
Journal:  Nat Immunol       Date:  2001-04       Impact factor: 25.606

3.  Mechanism of membrane damage mediated by human eosinophil cationic protein.

Authors:  J D Young; C G Peterson; P Venge; Z A Cohn
Journal:  Nature       Date:  1986 Jun 5-11       Impact factor: 49.962

4.  Ultrastructural evidence for release of major basic protein-containing crystalline cores of eosinophil granules in vivo: cytotoxic potential in Crohn's disease.

Authors:  A M Dvorak
Journal:  J Immunol       Date:  1980-07       Impact factor: 5.422

5.  Cationic proteins of human granulocytes. II. Separation of the cationic proteins of the granules of leukemic myeloid cells.

Authors:  I Olsson; P Venge
Journal:  Blood       Date:  1974-08       Impact factor: 22.113

6.  Crystal structure of eosinophil cationic protein at 2.4 A resolution.

Authors:  E Boix; D D Leonidas; Z Nikolovski; M V Nogués; C M Cuchillo; K R Acharya
Journal:  Biochemistry       Date:  1999-12-21       Impact factor: 3.162

7.  Mechanism of a reaction in vitro associated with delayed-type hypersensitivity.

Authors:  B R Bloom; B Bennett
Journal:  Science       Date:  1966-07-01       Impact factor: 47.728

8.  Comparative toxicity of purified human eosinophil granule cationic proteins for schistosomula of Schistosoma mansoni.

Authors:  S J Ackerman; G J Gleich; D A Loegering; B A Richardson; A E Butterworth
Journal:  Am J Trop Med Hyg       Date:  1985-07       Impact factor: 2.345

9.  Eosinophil cationic protein cDNA. Comparison with other toxic cationic proteins and ribonucleases.

Authors:  R L Barker; D A Loegering; R M Ten; K J Hamann; L R Pease; G J Gleich
Journal:  J Immunol       Date:  1989-08-01       Impact factor: 5.422

10.  The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor.

Authors:  T Calandra; J Bernhagen; R A Mitchell; R Bucala
Journal:  J Exp Med       Date:  1994-06-01       Impact factor: 14.307

View more
  6 in total

1.  CCR3 Blockade Attenuates Eosinophilic Ileitis and Associated Remodeling.

Authors:  Joanne C Masterson; Eóin N McNamee; Paul Jedlicka; Sophie Fillon; Joseph Ruybal; Lindsay Hosford; Jesús Rivera-Nieves; James J Lee; Glenn T Furuta
Journal:  Am J Pathol       Date:  2011-09-23       Impact factor: 4.307

2.  CD34 is required for infiltration of eosinophils into the colon and pathology associated with DSS-induced ulcerative colitis.

Authors:  Steven Maltby; Carolin Wohlfarth; Matthew Gold; Lori Zbytnuik; Michael R Hughes; Kelly M McNagny
Journal:  Am J Pathol       Date:  2010-08-09       Impact factor: 4.307

3.  The effect of calendula officinalis in therapy of acetic Acid induced ulcerative colitis in dog as an animal model.

Authors:  D Mehrabani; M Ziaei; S V Hosseini; L Ghahramani; A M Bananzadeh; M J Ashraf; A Amini; M Amini; N Tanideh
Journal:  Iran Red Crescent Med J       Date:  2011-12-01       Impact factor: 0.611

4.  Clinical value of serum eosinophilic cationic protein assessment in children with inflammatory bowel disease.

Authors:  Andrzej Wędrychowicz; Przemysław Tomasik; Stanisław Pieczarkowski; Kinga Kowalska-Duplaga; Zofia Grzenda-Adamek; Krzysztof Fyderek
Journal:  Arch Med Sci       Date:  2013-04-09       Impact factor: 3.318

5.  Outcomes of inflammatory bowel disease in patients with eosinophil-predominant colonic inflammation.

Authors:  Tarik Alhmoud; Anas Gremida; Diego Colom Steele; Imaneh Fallahi; Wael Tuqan; Nina Nandy; Mahmoud Ismail; Barakat Aburajab Altamimi; Meng-Jun Xiong; Audra Kerwin; David Martin
Journal:  BMJ Open Gastroenterol       Date:  2020-02-16

6.  Activated eosinophils in association with enteric nerves in inflammatory bowel disease.

Authors:  Claire M Smyth; Nadim Akasheh; Sara Woods; Elaine Kay; Ross K Morgan; Margaret A Thornton; Anthony O'Grady; Robert Cummins; Orla Sheils; Peter Smyth; Gerald J Gleich; Frank M Murray; Richard W Costello
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.